Krown S E
Semin Oncol. 1985 Dec;12(4 Suppl 5):13-7.
Renal-cell carcinoma rarely responds to cytotoxic chemotherapy, yet considerable evidence suggests that host factors may be capable of modifying the course of the disease. Although the mechanisms of interferon's antitumor effects are not well defined, the possibility that interferon might augment a host immune response provided a rationale for early clinical trials in this tumor. Investigations using various interferon alpha preparations (including interferons induced in human leukocytes and a human lymphoblastoid cell line) and recombinant interferons alfa-2a and alfa-2b have all provided evidence for antitumor activity. The overall major response rate with interferon alpha species in the 344 evaluable patients included in these 14 studies was 16.6% (57 patients), with response rates in individual studies ranging from 5% (1/21) to 31% (11/35). In renal-cell carcinoma, a response rate of the magnitude of 15% can be viewed with cautious optimism. Dose, schedule, route, and preparation have yet to be established for maximum efficacy, but progress has been made toward defining factors predicting response to treatment and mechanisms of interferon action.
肾细胞癌对细胞毒性化疗药物的反应很少见，但大量证据表明宿主因素可能能够改变疾病的进程。尽管干扰素抗肿瘤作用的机制尚未明确，但干扰素可能增强宿主免疫反应的可能性为该肿瘤的早期临床试验提供了理论依据。使用各种α干扰素制剂（包括在人白细胞和人淋巴母细胞系中诱导产生的干扰素）以及重组干扰素α-2a和α-2b进行的研究均提供了抗肿瘤活性的证据。在这14项研究纳入的344例可评估患者中，使用α干扰素制剂的总体主要缓解率为16.6%（57例患者），各研究中的缓解率从5%（1/21）到31%（11/35）不等。在肾细胞癌中，15%左右的缓解率可持谨慎乐观态度看待。为达到最大疗效，剂量、给药方案、给药途径和制剂尚未确定，但在确定预测治疗反应的因素和干扰素作用机制方面已取得进展。
